Investor Relations

Company Announcements

In the News

Investor Deck

X (Twitter)

We have entered into a clinical trial collaboration with leading Chinese pharma group Innovent Biologics to investigate the combination of IVX037 and their checkpoint inhibitor sintilimab in difficult to treat cancers:

We’ve received $3.77m R&D as part of the Australian Government’s R&D Tax Incentive programme:

The refund will contribute to the development of our investigational products IVX037 & IVX055 as well as other discovery programmes. #biotech #oncolytics

ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl’s presentation at The @Bell_Potter Healthcare Conference 2023 is now available.

Click here to view the presentation:

Load More